Genetronics appoints Singleton
US-based Genetronics Biomedical, a late stage developer of oncology and other therapies using electroporation to deliver drugs, nucleic acids, and genes, has appointed Dr Walter Singleton as vice president of clinical & regulatory affairs.
US-based Genetronics Biomedical, a late stage developer of oncology and other therapies using electroporation to deliver drugs, nucleic acids, and genes, has appointed Dr Walter Singleton as vice president of clinical & regulatory affairs.
Dr Singleton has over 25 years experience managing preclinical and clinical drug development programs and has held senior executive roles at leading pharmaceutical and biotechnology companies including Chugai Pharmaceuticals, Gensia and Pfizer.
'Dr. Singleton's extensive skills and expertise in drug development will be invaluable to us over the coming months as we anticipate having six active clinical programs, including two pivotal Phase III trials in the US and a Phase IV trial in Europe for the treatment of head and neck cancer,' said Dr Avtar Dhillon, Genetronics' president and ceo.
'Dr. Singleton's proven ability to manage clinical trials has contributed to the commercialisation of multiple drug products and supports our goals of advancing the clinical development and initiating the sales launch of our electroporation therapy system.'